Volume 5.47 | Dec 12

Prostate Cell News 5.47 December 12, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
A Yardstick to Measure the Malignancy of Prostate Cancer
A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists in a study of 7,700 samples of tumor tissue. [Press release from the University of Zurich (AlphaGalileo) discussing online prepublication in Nature Genetics] Press Release | Abstract
mTeSR™1: Most Published Feeder-Free hPSC Maintenance Medium. Click to View Top Applications
PUBLICATIONS (Ranked by impact factor of the journal)

GATA2 Facilitates Steroid Receptor Coactivator Recruitment to the Androgen Receptor Complex
Researchers demonstrate that GATA-binding protein 2 (GATA2) directly promotes expression of both full-length and splice-variant androgen receptor (AR), resulting in a strong positive correlation between GATA2 and AR expression in both prostate cancer cell lines and patient specimens. [Proc Natl Acad Sci USA] Abstract

The Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin Inhibits Bone Metastasis in a Mouse Model of Human Prostate Cancer
Scientists created Ad.dcn, a recombinant oncolytic adenovirus carrying the human decorin gene. Infection of PC-3 and DU-145, the human prostate tumor cells, with Ad.dcn or a non-replicating adenovirus Ad(E1-).dcn resulted in decorin expression; Ad.dcn produced high viral titers and cytotoxicity in human prostate tumor cells. [Gene Ther] Abstract

Omega-3 Fatty Acids and Other FFA4 Agonists Inhibit Growth Factor Signaling in Human Prostate Cancer Cells
Scientists examined effects of omega-3 fatty acids (n-3 FAs) in human prostate cancer cell lines. Initial studies established that the long-chain n-3 FAs, eicosapentaenoic acid and docosahexaenoic acid, inhibit proliferation of DU145 cells in response to lysophosphatidic acid, a mitogenic lipid mediator. [J Pharmacol Exp Ther] Abstract | Full Article

A Small Molecule Inhibitor of ETV1, YK-4-279, Prevents Prostate Cancer Growth and Metastasis in a Mouse Xenograft Model
SCID-beige mice were subcutaneously implanted with fusion-positive LNCaP-luc-M6 and fusion-negative PC-3M-luc-C6 tumors. Animals were treated with YK-4-279, and its effects on primary tumor growth and lung metastasis were evaluated. [PLoS One] Full Article | Press Release

P2X7 Mediates ATP-Driven Invasiveness in Prostate Cancer Cells
Scientists demonstrated that P2X7 was highly expressed in some prostate cancer cells. Down-regulation of P2X7 by siRNA significantly attenuated ATP- or BzATP-driven migration and invasion of prostate cancer cells in vitro, and inhibited tumor invasiveness and metastases in nude mice. [PLoS One] Full Article

Elevated Expression of Glutaminase Confers Glucose Utilization via Glutaminolysis in Prostate Cancer
Researchers show the loss of glutaminase function by RNA interference or inhibitor diminished the rates of glucose utilization, growth and invasiveness of prostate cancer cells. [Biochem Biophys Res Commun] Abstract

SUV39H1/H3K9me3 Attenuates Sulforaphane-Induced Apoptotic Signaling in PC3 Prostate Cancer Cells
Investigators demonstrated that sulforaphane induces posttranslational modification of histone methyltransferase SUV39H1 in metastatic, androgen receptor-negative PC3 prostate cancer cells. [Oncogenesis] Full Article


The Association of an Elevated Plasma Fibrinogen Level with Cancer-Specific and Overall Survival in Prostate Cancer Patients
In recent studies, an elevated plasma fibrinogen level has been associated with poor prognosis in different types of cancer. Researchers analyzed the prognostic impact of an elevated fibrinogen level in prostate cancer patients. [World J Urol] Abstract

Efficacy and Toxicity of Molecular Targeted Therapies in Combination with Docetaxel for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Phase III Randomized Controlled Trials
Scientists conducted a meta-analysis to assess the efficacy and toxicity of the addition of molecular targeted agents to docetaxel-based chemotherapy for the treatment of metastatic castration-resistant prostate cancer.
[J Chemother]

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
Immunotherapy in Prostate Cancer: Review of the Current Evidence
Prostate cancer shows several characteristics that make it a suitable candidate for immunotherapy, as recently exemplified by the approval of sipuleucel-T, the first vaccine to treat any malignancy. Here, the authors review different tumor-associated antigen immunotherapy strategies currently being investigated. [Clin Transl Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Paul G. Allen to Give $100 Million to Create Cell Science Institute
Philanthropist and entrepreneur Paul G. Allen announced a commitment of $100 million to create the Allen Institute for Cell Science in Seattle. Founded to investigate and model the complex living machinery of cells, the nonprofit Allen Institute for Cell Science and its inaugural project, the Allen Cell Observatory, will accelerate disease research around the world by creating and sharing reagents, data and dynamic, predictive models of cells. [Allen Institute for Cell Science] Press Release

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination with Merck’s KEYTRUDA® (Pembrolizumab) for Prostate Cancer
Advaxis, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application to conduct a Phase I/II clinical study to evaluate the combination of ADXS-PSA with KEYTRUDA® in patients with previously treated, metastatic castration-resistant prostate cancer. [Advaxis, Inc.] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Stem Cells in Drug Discovery
June 2-3, 2015
Cambridge, United Kingdom

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Research Associate Positions – Cancer Biology (Hollings Cancer Center)

NEW Postdoctoral Positions – Prostate Cancer Epigenetics and Genomics (UT Southwestern Medical Center at Dallas)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK Manchester Institute)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Postdoctoral Position – Prostate Cancer and Prostatic Diseases (Louisiana State University)

Postdoctoral Associate – Biomarkers Associated with Prostate Cancer (Duke Molecular Physiology Institute)

Postdoctoral Fellow – Metabolomics and Prostate Cancer (University of Maryland)

Research Technologist – Media Development (STEMCELL Technologies Inc.)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us